Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Author: Lisa Levin | March 06, 2023 02:25pm

Gainers

  • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb.
  • BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares jumped 59.5% to $17.34 after the company announced positive data for its phase 2 study of Infigratinib in Achondroplasia.
  • Avalon GloboCare Corp. (NASDAQ:ALBT) shares gained 53.5% to $3.3330.
  • Azul S.A. (NYSE:AZUL) gained 45.3% to $6.05 after the company announced a deal to reduce the immediate cash it must expend for leased property.
  • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 28.3% to $21.49. HC Wainwright & Co. maintained Kala Pharmaceuticals with a Buy and raised the price target from $12 to $20.Kala Pharmaceuticals recently said Q4 adjusted EPS results were higher year over year.
  • TCR2 Therapeutics Inc. (NASDAQ:TCRR) gained 28% to $1.55 after the company and Adaptimmune announced a strategic combination to create a preeminent cell therapy company for solid tumors.
  • Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) surged 25% to $2.28. Bellerophon Therapeutics announced a $5 million registered direct offering with institutional investor.
  • Genius Group Limited (NYSE:GNS) gained 22.5% to $4.4493.
  • Entera Bio Ltd. (NASDAQ:ENTX) rose 22.1% to $1.2206 after dropping 5% on Friday. Entera Bio recently announced the FDA's acceptance of a Type D meeting review to affirm design of the pivotal, Phase 3 protocol for EB613 PTH mini tablets, as the first oral osteoanabolic treatment of post-menopausal osteoporosis.
  • Gol Linhas Aéreas Inteligentes S.A. (NYSE:GOL) gained 21.8% to $2.51 amid strong Brazilian air travel numbers.
  • Orchard Therapeutics plc (NASDAQ:ORTX) jumped 21.3% to $0.57 after the company posted a narrower quarterly loss.
  • Borqs Technologies, Inc. (NASDAQ:BRQS) gained 17.2% to $0.2810. Borqs sees preliminary FY22 revenue of $53 million to $58 million.
  • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) jumped 17% to $0.9920.
  • Motorsport Games Inc. (NASDAQ:MSGM) jumped 16% to $11.16. Motorsport Games recently announced a $4.03 million registered direct offering.
  • Armata Pharmaceuticals, Inc. (NYSE:ARMP) gained 15.8% to $3.20 after the company announced topline data from the Phase 1b/2a SWARM-P.a. clinical trial of inhaled AP-PA02 in patients with cystic fibrosis.
  • Troika Media Group, Inc. (NASDAQ:TRKA) rose 15.6% to $0.5968 after dropping over 4% on Friday.
  • Snap Inc. (NYSE:SNAP) gained 11.3% to $11.85.
  • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 9.4% to $2.7251 after declining around 3% on Friday.
  • Secoo Holding Limited (NASDAQ:SECO) rose 7.5% to $1.0750 after dipping over 31% on Friday.
  • Hertz Global Holdings, Inc. (NYSE:HTZ) shares rose 7.4% to $20.18. Hertz Global will replace Pebblebrook Hotel Trust in the S&P MidCap 400 effective Monday, March 20.
  • BuzzFeed, Inc. (NASDAQ:BZFD) rose 6.7% to $1.6540. BuzzFeed is expected to release its Q4 financial results on Monday, March 13, 2023, after the closing bell.

Losers

  • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shares dipped 54.5% to $5.82 after the company announced its Phase 2A study of Zunsemetinib for Hidradentis Suppurativa did not meet its primary or secondary endpoints.
  • Embark Technology, Inc. (NASDAQ:EMBK) dropped 32.4% to $2.56. On March 1, 2023, Embark Technology board approved a reduction in its current workforce by approximately 230 employees.
  • Recon Technology, Ltd. (NASDAQ:RCON) fell 27.7% to $1.3073.
  • Rubius Therapeutics, Inc. (NASDAQ:RUBY) fell 22.3% to $0.0970 after gaining 10% on Friday.
  • Esperion Therapeutics, Inc. (NASDAQ:ESPR) fell 22% to $4.9450 after the company published new data on its treatment to reduce cardiovascular risk.
  • Yoshiharu Global Co. (NASDAQ:YOSH) dropped 21.5% to $1.7190.
  • Digital Media Solutions, Inc. (NYSE:DMS) dropped 19.3% to $0.9123. Digital Media Solutions, Inc. signed an agreement to acquire the HomeQuote.io home services marketplace from Customer Direct Group along with their brand direct international ad network.
  • Science 37 Holdings, Inc. (NASDAQ:SNCE) fell 17.7% to $0.2630 after the company posted a Q4 loss and files for mixed shelf of up to $100 million.
  • Adaptimmune Therapeutics plc (NASDAQ:ADAP) dropped 17.3% to $1.4550 after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
  • CECO Environmental Corp. (NASDAQ:CECO) dipped 13.3% to $13.50 after the company posted Q4 results.
  • Sidus Space, Inc. (NASDAQ:SIDU) fell 13.1% to $0.76.
  • Performance Shipping Inc. (NASDAQ:PSHG) shares fell 12.5% to $0.9703. Performance Shipping recently reported pricing of $12.5 million registered direct offering.
  • Addex Therapeutics Ltd (NASDAQ:ADXN) dropped 12.1% to $1.6087.
  • ObsEva SA (NASDAQ:OBSV) fell 9.7% to $0.2074. ObsEva shares jumped 117% on Friday following the purchase of 4 million shares by a company director.
  • Unisys Corporation (NYSE:UIS) fell 9.1% to $4.4350.
  • Oculis Holding AG (NASDAQ:OCS) dropped 8.3% to $9.98.
  • IAA, Inc. (NYSE:IAA) fell 7.6% to $38.06.
  • Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares fell 7.5% to $0.3998 after gaining 11% on Friday. Vivos Therapeutics recently acquired product rights and patents from Advanced Facialdontics, LLC.

Now Read This: Top 5 Utilities Stocks That Could Blast Off In March

Posted In: ACRS ADAP ADXN ALBT ARMP AZUL BBIO BCAN BLCM BLPH BRQS BZFD CECO DMS EMBK ENTX ESPR GNS GOL HTZ

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist